Navigation Links
Clarification on Press Release Issued Earlier Today: Targeted Genetics Confirms Positive, Interim Phase 1/2 Study Findings
Date:5/30/2008

Trial Demonstrates Safety and Preliminary Efficacy and Supports Further

Clinical Development of tgAAC94

BOSTON and SEATTLE, May 30 /PRNewswire-FirstCall/ -- Targeted Genetics Corporation (Nasdaq: TGEN) issued a news release earlier today, entitled "Targeted Genetics Reports Additional Data From Inflammatory Arthritis Clinical Trial," announcing additional interim data from its Phase 1/2 clinical study of tgAAC94 in patients with inflammatory arthritis. Pervin Anklesaria, Ph.D., vice president of therapeutic development for Targeted Genetics, presented the data in an oral presentation at the 11th Annual Meeting of the American Society of Gene Therapy (ASGT) in Seattle.

To clarify, the data demonstrated that a 30 percent decrease in the global visual analog scale (VAS) was experienced by 21/50 (42 percent) of subjects and 3/16 (19 percent) placebo subjects 12 weeks after the first injection. The global VAS is a clinically meaningful and commonly used pain assessment tool to help patients describe the intensity of their pain. A two-point decrease in swelling was noted in 8/50 (16 percent) treated subjects and 3/16 (19 percent) placebo subjects 12 weeks after the first injection. It appears that the patient-reported outcome measures of clinical response yielded greater differentiation between tgAAC94 and placebo than physical examination. In a subset of subjects, MRI was also performed on treated joints and a decrease in effusion was noted in 1/10 subjects tested.

"We are very pleased that the trial met safety endpoints and demonstrated preliminary efficacy," said H. Stewart Parker, president and chief executive officer of Targeted Genetics. "We believe the data suggest that tgAAC94 has the potential
'/>"/>

SOURCE Targeted Genetics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
2. Pressure BioSciences, Inc. Issued First Patent in Canada
3. Interventional Cardiologists Nico Pijls, Bernard De Bruyne to Discuss Benefits of Measuring Coronary Pressure in Improving Multivessel PCI at ESC Congress 2007
4. Pressure BioSciences, Inc. Announces CE Mark Approval and Compliance with the IEC 61010-1 Standard for a Second PCT-based Instrument, the Barocycler NEP2320
5. Amgen and Genentech Brace Themselves for Heavy Pressure From Biogenerics Manufacturers
6. Three Studies by Independent Scientists Highlighting Pressure Cycling Technology (PCT) to be Presented this Week at the British Mass Spectrometry Societys 29th Annual Meeting
7. Caliper Life Sciences Introduces High Throughput RNA Assay to Improve Workflow in Gene Expression Studies
8. Pressure BioSciences, Inc. Provides Corporate Update
9. Forest Laboratories Lexapro and Generics-Dominated Fluoxetine Lead First-Line Therapy in the Treatment for Major Depression
10. Results of Colon Cancer Study Utilizing Pressure Cycling Technology (PCT) Presented at the American College of Gastroenterology Annual Scientific Meeting
11. The sensitive side of carbon nanotubes: Creating powerful pressure sensors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... N.J. , April 30, 2015  Roka Bioscience, ... focused on providing advanced testing solutions for the detection ... results for the first quarter of 2015 on May ... Roka Bioscience will also host a conference ... 2015 to discuss its first quarter financial results. During ...
(Date:4/30/2015)... 2015 Nitto Avecia, a leading ... increased capacity and production capability to serve biotechnology ... and service fulfillment continues to drive Nitto Avecia ... throughput capacities. , In Fall 2014, ... process equipment at its Milford, MA facility, which ...
(Date:4/30/2015)...  The Paul G. Allen Family Foundation announced today ... six groups of researchers with projects at the frontier ... growing mature human brain cells in the laboratory. The ... over three years.  "This new cohort ... significant because the field of neuronal maturation is at ...
(Date:4/30/2015)... April 30, 2015 WuXi PharmaTech (Cayman) Inc. ... leading global contract R&D services provider, today announced that ... proposal letter, dated April 29, 2015, from a consortium ... (the "Chairman"), founder, chairman and chief executive officer of ... that proposes a transaction (the "Transaction") involving the acquisition ...
Breaking Biology Technology:Roka Bioscience to Report First Quarter 2015 Financial Results On May 7, 2015 2Biotechnology Manufacturer Nitto Avecia Expands Capacity to Meet Client Demand 2The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 2The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 3The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 4The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 5WuXi PharmaTech Announces Receipt of Proposal 2WuXi PharmaTech Announces Receipt of Proposal 3WuXi PharmaTech Announces Receipt of Proposal 4WuXi PharmaTech Announces Receipt of Proposal 5WuXi PharmaTech Announces Receipt of Proposal 6
... Annual Observance To Draw Attention To ,The Sneak Thief ... an effort to combat one of the,main causes of ... World Glaucoma Patient Organization have announced the first annual,World ... The day will be marked,by awareness and educational events ...
... and CLAREMONT, Calif., Jan. 30 /Xinhua-PRNewswire-FirstCall/ --,Kiwa Bio-Tech ... the volume of bio-enhanced feed products sold during ... quarter of 2007 and increased,25% over the same ... Feed Co., Ltd. ("Kiwa Tianjin") is a joint-venture ...
... Tengion Inc., a clinical,stage regenerative medicine company focused ... that Steven Nichtberger, M.D.,President and Chief Executive Officer, ... Biotechnology and Medical Device Conference on,Tuesday, February 5, ... be held at,the Grand Hyatt Hotel in New ...
Cached Biology Technology:World Glaucoma Day Set for March 6th 2Kiwa Bio-Tech Animal Feed Volume Increased 25% in Fourth Quarter of 2007 2
(Date:4/14/2015)... 14, 2015  HYPR Corp. today announced it ... ) Alliance tm , an industry consortium transforming ... to share technology and collaborate to deliver open ... more secure and private, and easier to use. ... that protects sensitive user information and eliminates the ...
(Date:4/9/2015)... 2015 Synaptics Inc. (NASDAQ: SYNA ), a ... it will report financial results for the third quarter ... the close of market. The company will host a ... p.m. PT (5:00 p.m. ET), during which management may ... the live call, analysts and investors should dial 888-438-5524 ...
(Date:4/2/2015)... , April 2, 2015 ... Q1 2015 attributed to somewhat higher than 125 MSEK. ... the year-end report 2014 that revenues for Q1 2015 ... the company reported for Q4 2014. The operating result ... be negative. The complete interim report will as previously ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Synaptics to Report Third Quarter Results on April 23 2Fingerprint Cards Revises Revenues for Q1 2015 2
... risks posed by pharmaceuticals are not enough to protect ... of Gothenburg (Sweden) who is calling for better environmental ... the combined effects of different drugs to reflect the ... Brosch from the Department of Plant and Environmental Sciences ...
... of scientists from Singapore led by the Genome Institute ... Cell Biology (IMCB), two biomedical research institutes of ... discovered the most important genes in human embryonic stem ... stem cells work. Their research, published in top scientific ...
... National Laboratory researcher Bette Korber is part of an ... the first human trial of a mosaic HIV vaccine ... the virus that causes AIDS by attempting to address ... design: the virus,s extensive genetic diversity. The team ...
Cached Biology News:Environmental risk assessment of pharmaceuticals inadequate 2Singapore scientists first to perform genome-wide study of human stem cells 2Consortium to design human trials of mosaic HIV vaccine 2
Rabbit polyclonal to hCG ( Abpromise for all tested applications). entrezGeneID: 1081 SwissProtID: P01215...
Anti-HumanLactoferrin...
Rabbit monoclonal [EP881Y] to EEF2K ( Abpromise for all tested applications). Antigen: Synthetic peptide corresponding to residues in the C-terminal of human EEF2K. Entrez GeneID: 29904 S...
ICAD Purified Anti-Mouse clone Polyclonal, Isotype Rabbit Ig, 200 µl Consult technical datasheet for details....
Biology Products: